Bridging Sunitinib Exposure to Time‐to‐Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker

Hepatocellular carcinoma (HCC) is third in cancer‐related causes of death worldwide and its treatment is a significant unmet medical need. Sunitinib is a selective tyrosine kinase inhibitor of the angiogenic biomarker: soluble vascular endothelial growth factor receptor‐2 (sVEGFR2). Sunitinib failed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CPT: pharmacometrics and systems pharmacology 2016-06, Vol.5 (6), p.297-304
Hauptverfasser:	Ait‐Oudhia, S, Mager, DE, Pokuri, V, Tomaszewski, G, Groman, A, Zagst, P, Fetterly, G, Iyer, R
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - pharmacokinetics Angiogenesis Inhibitors - pharmacology Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - pharmacology Biomarkers Biomarkers, Tumor - metabolism Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Clinical outcomes Disease Progression Drug dosages Hematology Humans Indoles - administration & dosage Indoles - pharmacokinetics Indoles - pharmacology Inhibitor drugs Kinases Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - pathology Medical prognosis Models, Theoretical Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology NMR Nuclear magnetic resonance Original Patients Pilot Projects Pyrroles - administration & dosage Pyrroles - pharmacokinetics Pyrroles - pharmacology Survival Rate Targeted cancer therapy Time Factors Vascular endothelial growth factor Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!